Abstract
Introduction: History of prior biologic treatment may indicate disease more recalcitrant to subsequent biologics in patients with moderate to severe plaque psoriasis. We examined clinical and health-related quality of life (HRQoL) outcomes in bimekizumab (BKZ)-treated patients with prior systemic nonbiologic treatment vs patients with prior biologic treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
